We performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension.

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

The T-ACT study evaluated the continuous use of trastuzumab combined with paclitaxel compared with paclitaxel monotherapy in patients with previously treated HER2-positive G/GEJ cancer 24; however, ...

Herceptin is approved in combination with the chemotherapy drugs cisplatin, and either capecitabine or 5-fluorouracil, for metastatic HER2-positive stomach cancer or cancer of the gastroesophageal ...

Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

Because of that, we have done studies that suggested that Herceptin added to chemotherapy in the setting of metastatic breast cancer can also lead to an improvement in breast cancer.

Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) with endocrine therapy but without chemotherapy has been shown to potentially be an effective treatment for patients with HER2-positive ...

Herceptin may be prescribed with chemotherapy drugs, including paclitaxel and docetaxel. Talk with your doctor if you’re concerned about hair loss and your cancer treatment. This side effect isn ...

One common treatment for those with HER2-positive breast cancer begins with one or more chemotherapy drugs in addition to trastuzumab, which is an anti-HER2 antibody.

We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients ...